Search for Clinical Trial Results

Sponsored By

Salivary Gland Neoplasms - 16 Studies Found

Status Study
Completed Study Name: Activity of Sorafenib in Salivary Gland Cancer
Condition: Salivary Gland Cancer
Date: 2012-04-06
Interventions: Drug: Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
Active, not recruiting Study Name: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Condition:
  • Recurrent Salivary Gland Cancer
  • Stage IVA Salivary Gland Cancer
  • Major Salivary Gland Carcinoma
  • Minor Salivary Gland Carcinoma
  • Biological: Ipilimumab Given I
Active, not recruiting Study Name: Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
Condition: Salivary Gland Carcinoma
Date: 2015-03-13
Interventions: Drug: pazopanib treatment will be given until progression or unacceptable toxicity .
<<< Previous